SCHEMBL6345812

SCHEMBL6345812

CCCS(=O)(=O)NC1CCCCC1(F)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.46
AR P10275 5/20 0.45
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
MGLL Q99685 3/20 0.39
ADAM17 P78536 1/20 0.39
KDM4E B2RXH2 1/20 0.39
KMT2A Q03164 1/20 0.39
ELOVL6 Q9H5J4 1/20 0.38
MMP2 P08253 1/20 0.38
MMP13 P45452 1/20 0.38
FOXM1 Q08050 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6345535 0.88 RORC (0.38) RORCARADAM17ELOVL6MMP2
SCHEMBL6351604 0.88 PSEN1 (0.39) SMN1; SMN2KMT2AELOVL6MMP2MMP13
SCHEMBL6348256 0.87 AR (0.44) RORCARRAB9ASMN1; SMN2NPC1
SCHEMBL6354897 0.86 PSEN1 (0.44)
SCHEMBL6354891 0.86 RORC (0.46) RORCARRAB9ASMN1; SMN2NPC1
SCHEMBL6345809 0.86 RORC (0.46) RORCARRAB9ASMN1; SMN2NPC1
SCHEMBL6345808 0.86 RORC (0.46) RORCARRAB9ASMN1; SMN2NPC1
SCHEMBL6342954 0.84 PSEN1 (0.39) SMN1; SMN2ADAM17KMT2AELOVL6MMP2
SCHEMBL6344554 0.84 ADAM17 (0.43) RORCADAM17KMT2AMMP13
SCHEMBL6347843 0.84 SLC6A4 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 RORC 2136/4885AR 3446/4885RAB9A 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.